Verona Pharma plc Verona Pharma To Present Phase 2b Copd Symptom And Quality Of Life Data With Ensifentrine At Chest 2020

 
TIDMVRP 
 
 
   Posters highlight ensifentrine's potential to provide rapid benefits 
 
   LONDON and RALEIGH, N.C., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Verona 
Pharma plc (AIM: VRP) (Nasdaq: VRNA) ("Verona Pharma"), a clinical-stage 
biopharmaceutical company focused on respiratory diseases, announces 
that it will present new analyses from a Phase 2b clinical trial with 
nebulized ensifentrine in chronic obstructive pulmonary disease ("COPD") 
at CHEST Annual Meeting ("CHEST") 2020 taking place on October 18-21. 
The data are published in the CHEST Annual Meeting online supplement. 
 
   The posters present further analysis of Phase 2b data, first reported by 
Verona Pharma on January 13, 2020 
https://www.globenewswire.com/Tracker?data=SUTCRp0UxBsvD-tUy10edVFo38iyIwfBiWcu0Y7IcF-iZ-NtPJMrZVYLl9hzaHYzmZYGiZZbh4HXv0Vz9hu5hfuBapB0iYBQkPw3SGybTYqhciK8uHynt0nW3WrwHVykLwNfarD15NAYG80n5VZCtTwlB3H5nMGuT24v5KAzuYjs-FlbHKE-qlmTmeMuNTQr 
, demonstrating that nebulized ensifentrine added to tiotropium 
(Spiriva(R) Respimat(R) ), a long acting anti-muscarinic ("LAMA") 
bronchodilator, provides meaningful additional improvement in quality of 
life as measured by St. George's Respiratory Questionnaire: COPD 
(SGRQ-C). This was shown in symptomatic COPD patients over 4 weeks, 
including statistically significant improvement in both activity and 
impacts subscales compared to placebo added on to tiotropium. 
Importantly, a responder analysis of the proportion of patients 
achieving a clinically important difference in quality of life on the 
SGRQ-C showed responses in favor of ensifentrine, which were 
particularly notable in COPD patients who were not reversible to 
albuterol. An evaluation of inspiratory capacity over 4 weeks 
demonstrated a clinically meaningful and statistically significant 
improvement in inspiratory capacity ("IC"). Improvements in IC have been 
shown to correlate with improvements in dyspnea, suggesting that 
ensifentrine improves symptoms and quality of life via a physiological 
mechanism. 
 
   In addition to the Phase 2b data with nebulized ensifentrine, Verona 
Pharma will highlight Phase 2 data with a pressurized metered dose 
inhaler ("pMDI") formulation of ensifentrine. This data showed a rapid 
and meaningful bronchodilatory response in COPD patients following a 
single dose of ensifentrine pMDI. This effect was sustained for 12 
hours. Data from this study were first reported on March 31, 2020 
https://www.globenewswire.com/Tracker?data=aYsxIFF6S9YvRdISMJJk6Q0AW4TuFGzNFL_iQFG8NWD-41JdJiTqnXH-c4LLSD5zfgTHfxRygOfaqKol8IEeDfKfR4WND6__BBjNDOWUQ4KR-lrYtpI4FQzNjlrT0mShtEYShw40_Kup8lvA87b-qdWCC9TeS3O5tR97wAEEPkxsv96fFnx8NpqOQ0_5_7oq 
. Notably, the Company will also present pre-clinical data demonstrating 
the anti-inflammatory effects of ensifentrine, which further support its 
dual mechanism of action as an inhibitor of phosphodiesterases ("PDE") 3 
and 4. 
 
   Details of Verona Pharma's abstracts are listed below. 
 
   e-Poster: P1491 Ensifentrine added to tiotropium over 4 weeks provides 
additional improvement in COPD quality of life 
https://www.globenewswire.com/Tracker?data=9M14PsDYgTur0QOChBfQYfWg0EG5RYIiACj1-PqEiotn8qUTWckVh1p5G7z1xnNdCKp7EN7fXCFOHJTtrfdIbW3s-rpnc6z-367-g7ynPYMMkyy-1Q8AfBPxWXO7WvDBiyAws1Viisl2vrUcJkNY6MG_RyZASnyQF5cktrYufocxXS9rLn7cMSgVNCIVaNyEVrnSIIXguNR_WLJAoScxTeO6ekEXy8Sa1Hcjke0fMC6jXm0IH_4i1ffRsOceMXxSAb1mKzHGPgqjGiC_J0trEQ== 
 
 
   Author: Kathleen Rickard, M.D., CMO, Verona Pharma 
 
   Session: Obstructive Lung Disease Posters 
 
   e-Poster: P1490 
https://www.globenewswire.com/Tracker?data=3BLCe60MeS-hfTa1yAlr5ipdDwr1PS7SwQ5ghSKpB27Y_YYSiCGRumDEVWAF22obt-nnpAVNX2iKvApLJlVeD8ReHY5tgzU7JbZ_kU9sJaVYpPo05weR8sBsdcEYJ29bR0kJvO_tS2owUy6G-cZHtw== 
Ensifentrine added on to tiotropium significantly improves inspiratory 
capacity in 
https://www.globenewswire.com/Tracker?data=vutDiweYuUL8E7iU_ufi0W-qH43Xe7X1FADfCm8lgjZ_S48kkd5gT4l28DebZYj_muut9gGBWn83XJWTrrA6h0k5HY8L11E7MIKQjKlNKg-inGOVSWff89TlxV4Jgg6Bi0NSY82xrOr_SkIMySOAZ3xnW2ULlt4DINeFVHiZvm9pSNnTYzacDP-dg7hZUOSOwC6Tq1UxGMzbWqfqPBnBXf48AFmb8JTNDDnJwQeC6BE= 
patients with 
https://www.globenewswire.com/Tracker?data=8xmqcVQwqYss9Pd1v9vDmtyAHEpMcBPaf7Kj-IpDWyfoZ_BRGJYSAExr8uhrKDIRi9l9YZVkBHvZOycsTXa-mlY5pKRvKGM9sujNS_ypQPc5eRfhXxHTES0s2oSuB6EBs8DYAmVJ-Qzn5Q61I_j1GA== 
symptomatic COPD 
https://www.globenewswire.com/Tracker?data=czE1Xutsaw7EFkBrOTx0Gw_E_5H7gsp2qet5Rm5a3A4o_FyND4Nmcn8Y-dAs443sJMMLEYmwow7zFKAQ0xi6wrEyG-EtjskitTwB-2EJUbCMQRDcciRaU0pbXn9qVEVcAUnYeKnRyQ-ro3bjq1KC5g== 
 
 
   Author: Kathleen Rickard, M.D., CMO, Verona Pharma 
 
   Session: Obstructive Lung Disease Posters 
 
   e-Poster: P1489 
https://www.globenewswire.com/Tracker?data=rjzCKmRq2oqmdD3d9-2aLHTetkTnBnQgjBBfXMx1qaxQ5zCrkHsRFo6XCJb-HQ8l8taWStxJ5LO-wQ6A_4pjWVf3LWs2oyLeeEM1FNcfgxVTxbH-fLkwtN7ybJGRN1W40sbmNsd9N2UlqxaGOWgOBA== 
Ensifentrine, a novel dual phosphodiesterase (PDE) 3 and 4 inhibitor, 
provides effective bronchodilation when administered by metered dose 
inhaler in patients with COPD 
https://www.globenewswire.com/Tracker?data=vutDiweYuUL8E7iU_ufi0b0WX-ANmJJZmfBrm_Fz28xJ_2yHOFeBjpJxU0PH4DIGgsnZVX1_vKgNeWHqvvVekaxEatbBWhaHYdfjVl5KiUG1BvrK0Vv8d9R2JcWIWydbEvPhEjM4KnEQHvQvZrdW4xvZUFGrVV4X-p07jMFBhFZEWqFoz1crjXAjlzuX2EK4fbL14ONLifVQeOQjfWlqX8SigJhAZw-xjb5deXwyIYeP9O0PwSBS5pOBe4LefFUQ_HjgJK2ZcGZ_rpxgEH8uEjYOoYx-770oe4uKuqmHGyh0E1QTFOKrtZdc3XVfd4BDEnyTfXzSHIEp-AkNzt1PECHhE7I-85wfMmgcGbMtBUE= 
 
 
   Presenter: Tara Rheault, Ph.D., Vice President, R&D and Global Project 
Management, Verona Pharma 
 
   Session: Obstructive Lung Disease Posters 
 
   e-Poster: P1944 
https://www.globenewswire.com/Tracker?data=pyfgYmMmWXqDFfEe8iYO_NCe9Wv4eY5JQ1rNTVUeFwimwzBPpCm8bddAddY43Yp30E49i0JcXNkjbSB-f4NHf-H8luPPcJaglkpDUyAVcPDVWrwlBT8LtHUIi3JHw7WO74w7Y7L03NZVhDt5SB_Gow== 
A 
https://www.globenewswire.com/Tracker?data=0RxS2wLFlLvmDiX3qE7QdcTwL-P6rUt7Odf1r_A2fmhtU9HC4fLwJz063jx-HgIua6jGYVx9D4DbG227xZhUciAIqH_fFMbUKT8gr7Th-eACCMcZvCG04WFXr-qnfB9T 
nti-inflammatory pharmacology of ensifentrine 
https://www.globenewswire.com/Tracker?data=5Aqu8qYDlbJFgwvrQgL_q0edXbK8IwP8VQVmQBySmjN9W5y6LWWm1knrqsVLyhsMEw2rkJ9FFV_anUsmOsJi9Xq4zdUfDlMFc7kUuZJJ00YOwiZZTBGXuqVvbMdXbI9vFSB96BCF3-fNfFbTwpZ4g7xesHmU1SPhZnJNnFfz28AI4_2MMGxVpr1sQmtpaNHp 
 
 
   Presenter: Tara Rheault, Ph.D., Vice President, R&D and Global Project 
Management, Verona Pharma 
 
   Session: Respiratory Care Posters 
 
   For further information, please contact: 
 
 
 
 
Verona Pharma plc                             Tel: +44 (0)20 3283 4200 
David Zaccardelli, Chief Executive Officer    info@veronapharma.com 
Victoria Stewart, Director of Communications 
 
N+1 Singer                                    Tel: +44 (0)20 7496 3000 
 (Nominated Adviser and UK Broker) 
Aubrey Powell / George Tzimas / Iqra Amin 
(Corporate Finance) 
Tom Salvesen (Corporate Broking) 
 
Optimum Strategic Communications              Tel: +44 (0)203 950 9144 
 (European Media and Investor Enquiries)       verona@optimumcomms.com 
Mary Clark / Eva Haas / Shabnam Bashir 
 
Argot Partners                                Tel: +1 212-600-1902 
 (U.S. Investor Enquiries)                     verona@argotpartners.com 
Kimberly Minarovich / Michael Barron 
 
 
   About COPD 
 
   COPD is a progressive and life-threatening respiratory disease without a 
cure. It is the third leading cause of death globally, according to the 
World Health Organization. The condition damages the airways and the 
lungs, leading to debilitating breathlessness that has a devastating 
impact on performing basic daily activities such as getting out of bed, 
showering, eating and walking. U.S. sales of medicines used for chronic 
maintenance therapy of COPD were $9.6 billion in 2019. About 1.2 million 
U.S. COPD patients on dual/triple inhaled therapy, long-acting 
beta-agonist ("LABA")/long-acting muscarinic antagonist ("LAMA") +/- 
inhaled corticosteroid ("ICS") remain uncontrolled, experiencing 
symptoms that impair quality of life. These patients urgently need 
better treatments. 
 
   About Ensifentrine 
 
   Ensifentrine (RPL554) is an investigational, first-in-class, inhaled, 
dual inhibitor of the enzymes phosphodiesterase 3 and 4 ("PDE3" and 
"PDE4"). This dual inhibition enables it to combine both bronchodilator 
and anti-inflammatory effects in one compound. Ensifentrine also 
activates the Cystic Fibrosis Transmembrane Conductance Regulator 
("CFTR"), which is beneficial in reducing mucous viscosity and improving 
mucociliary clearance. Ensifentrine's mechanism of action has the 
potential to alleviate respiratory symptoms such as breathlessness and 
cough and work against inflammation associated with COPD or inflammation 
triggered by viruses. 
 
   Ensifentrine has demonstrated significant and clinically meaningful 
improvements in both lung function and symptoms, including 
breathlessness, in Verona Pharma's Phase 2 clinical studies in patients 
with moderate to severe Chronic Obstructive Pulmonary Disease ("COPD"). 
In addition, nebulized ensifentrine showed further improved lung 
function and reduced lung volumes in COPD patients taking standard 
short- and long-acting bronchodilator therapy, including maximum 
bronchodilator treatment with dual/triple therapy. Ensifentrine has been 
well tolerated in clinical trials involving more than 1,300 subjects to 
date. 
 
   About Verona Pharma 
 
   Verona Pharma is a clinical-stage biopharmaceutical company focused on 
developing and commercializing innovative therapies for the treatment of 
respiratory diseases with significant unmet medical needs. If 
successfully developed and approved, Verona Pharma's product candidate, 
ensifentrine, has the potential to be the first therapy for the 
treatment of respiratory diseases that combines bronchodilator and 
anti-inflammatory activities in one compound. The Company is evaluating 
nebulized ensifentrine in its Phase 3 clinical program ENHANCE 
("Ensifentrine as a Novel inHAled Nebulized COPD thErapy") for COPD 
maintenance treatment. The Company raised gross proceeds of $200 million 
through a private placement in July 2020 and expects the funds to

support its operations and Phase 3 clinical program into 2023. Two 
additional formulations of ensifentrine are currently in Phase 2 
development for the treatment of COPD: dry powder inhaler ("DPI") and 
pressurized metered-dose inhaler ("pMDI"). Ensifentrine is in a pilot 
clinical study in patients hospitalized with COVID-19 and has potential 
applications in cystic fibrosis, asthma and other respiratory diseases. 
For more information, please visit www.veronapharma.com. 
 
   Forward-Looking Statements 
 
   This press release contains forward-looking statements. All statements 
contained in this press release that do not relate to matters of 
historical fact should be considered forward-looking statements. These 
forward-looking statements are based on management's current 
expectations. These statements are neither promises nor guarantees, but 
involve known and unknown risks, uncertainties and other important 
factors that may cause our actual results, performance or achievements 
to be materially different from our expectations expressed or implied by 
the forward-looking statements. Any such forward-looking statements 
represent management's estimates as of the date of this press release. 
While we may elect to update such forward-looking statements at some 
point in the future, we disclaim any obligation to do so, even if 
subsequent events cause our views to change. These forward-looking 
statements should not be relied upon as representing our views as of any 
date subsequent to the date of this press release.

(END) Dow Jones Newswires

October 13, 2020 02:00 ET (06:00 GMT)

Verona Pharma (LSE:VRP)
過去株価チャート
から 12 2024 まで 1 2025